296 related articles for article (PubMed ID: 24832199)
21. Testosterone and the prostate: implications for the treatment of hypogonadal men.
Holyoak JD; Crawford ED; Meacham RB
Curr Urol Rep; 2008 Nov; 9(6):500-5. PubMed ID: 18947516
[TBL] [Abstract][Full Text] [Related]
22. Update on Testosterone Replacement Therapy in Hypogonadal Men.
Leung KM; Alrabeeah K; Carrier S
Curr Urol Rep; 2015 Aug; 16(8):57. PubMed ID: 26077352
[TBL] [Abstract][Full Text] [Related]
23. Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men.
Siltari A; Murtola TJ; Kausz J; Talala K; Taari K; Tammela TL; Auvinen A
Acta Oncol; 2023 Dec; 62(12):1898-1904. PubMed ID: 37971326
[TBL] [Abstract][Full Text] [Related]
24. Testosterone Therapy: What We Have Learned From Trials.
Corona G; Torres LO; Maggi M
J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
[TBL] [Abstract][Full Text] [Related]
25. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
[TBL] [Abstract][Full Text] [Related]
26. Late-life onset hypogonadism: a review.
Bassil N; Morley JE
Clin Geriatr Med; 2010 May; 26(2):197-222. PubMed ID: 20497841
[TBL] [Abstract][Full Text] [Related]
27. [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].
Rinnab L; Gust K; Hautmann RE; Küfer R
Urologe A; 2009 May; 48(5):516-22. PubMed ID: 19296069
[TBL] [Abstract][Full Text] [Related]
28. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
29. 'Case of the Month' from Herlev and Gentofte Hospital, Denmark: metastatic prostate cancer in a man with late-onset hypogonadism following testosterone-replacement therapy.
Guldbaek MV; Fode M; Jensen CFS; Sønksen J; Østergren PB
BJU Int; 2021 Oct; 128(4):428-430. PubMed ID: 34581479
[No Abstract] [Full Text] [Related]
30. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
[TBL] [Abstract][Full Text] [Related]
31. EMAS position statement: Testosterone replacement therapy in the aging male.
Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
[TBL] [Abstract][Full Text] [Related]
32. Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency.
Vartolomei MD; Kimura S; Vartolomei L; Shariat SF
Eur Urol Focus; 2020 Jan; 6(1):170-177. PubMed ID: 30017901
[TBL] [Abstract][Full Text] [Related]
33. [Testosterone replacement therapy for hypogonadism in men with prostate cancer].
Jensen CF; Fode M; Østergren P; Sønksen J
Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152
[TBL] [Abstract][Full Text] [Related]
34. Testosterone replacement therapy and prostate cancer: a word of caution.
Brand TC; Canby-Hagino E; Thompson IM
Curr Urol Rep; 2007 May; 8(3):185-9. PubMed ID: 17459266
[TBL] [Abstract][Full Text] [Related]
35. Influence of androgen receptor CAG polymorphism on sexual function recovery after testosterone therapy in late-onset hypogonadism.
Tirabassi G; Corona G; Biagioli A; Buldreghini E; delli Muti N; Maggi M; Balercia G
J Sex Med; 2015 Feb; 12(2):381-8. PubMed ID: 25443437
[TBL] [Abstract][Full Text] [Related]
36. Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review.
Hellstrom WJ; Paduch D; Donatucci CF
Int Urol Nephrol; 2012 Feb; 44(1):61-70. PubMed ID: 21152980
[TBL] [Abstract][Full Text] [Related]
37. Prospective assessment of health-related quality of life in men with late-onset hypogonadism who received testosterone replacement therapy.
Sumii K; Miyake H; Enatsu N; Matsushita K; Fujisawa M
Andrologia; 2016 Mar; 48(2):198-202. PubMed ID: 25988884
[TBL] [Abstract][Full Text] [Related]
38. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.
Kaplan AL; Trinh QD; Sun M; Carter SC; Nguyen PL; Shih YT; Marks LS; Hu JC
J Sex Med; 2014 Apr; 11(4):1063-1070. PubMed ID: 24443943
[TBL] [Abstract][Full Text] [Related]
39. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
Gould DC; Kirby RS
Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
[TBL] [Abstract][Full Text] [Related]
40. 'Forever Young'-Testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises.
Busnelli A; Somigliana E; Vercellini P
Hum Reprod; 2017 Apr; 32(4):719-724. PubMed ID: 28333214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
